V I S I T
WORLD’S CLINICAL LABORATORY NEWS LEADER ISSN 1068-1760
Vol. 38 No.4 • 6-7/2021
DAILY CLINICAL LAB NEWS
®
I
N
T
LAMP Assay Diagnoses High HBV DNA Levels orldwide a population estimated at some 260 million is chronically infected with hepatitis B virus (HBV) and 887,000 annually die from cirrhosis or liver cancer. Since over 95% of HBV-infected people live in low and middle income countries
W
E
R
N
A
T
I
O
Comprehensive Genomic Profiling Test: Analytic Validation and Clinical Utilization ancer has a high clinical burden and oncology therapies are expensive. It is estimated that 1,898,160 new cancer cases will be diagnosed and over 608,570 deaths are projected to occur in the USA in 2021. The prevalence of cancer is expected to rise over
C
time, providing an expanding unmet need for genomic tests to help physicians treat patients in a more precise manner. Identification of genomic alterations by Next Generation Sequencing (NGS) has become an efficient clinical tool, particularly
Cont’d on page 9
Cont’d on page 12
Antibody Test Screens for COVID -19 Vaccine Induced Blood Clots
N
A
L
Test for Risk of Urinary Uric Acid Crystallization ric acid (UA) kidney stones account for 10% to 11% of all kidney stones, and this percentage has increased over time. An accurate, rapid, simple, and low-cost test is needed to distinguish urine that is susceptible and resistant to the formation of UA crystals. Renal stone formation is a multifactorial process that is affected by urine composition and
U
Cont’d on page 14
Test Offers Biopsy-Free Colon Cancer Diagnosis
T
newly developed liquid biopsy test detects persistent circulating tumor DNA (ctDNA) after curative surgery and can identify patients with minimal residual disease (MRD) who will ultimately relapse. Most ctDNA MRD assays require tumor sequencing to identify tumor-derived mutations and to facilitate ctDNA detection. This approach requires both a
he world’s first diagnostic testing menu for suspected vaccine induced immune thrombotic-thrombocytopenia (VITT) aims to aid physicians in managing suspected blood clots.
A
See article on page 9
Cont’d on page 27 V
I
S
I
LINKXPRESS COM R E A D E R
Portable COVID-19 Test Detects SARS-CoV-2 Within One Second
T
S E R V I C E
®
P O R T A L
Renew/Start your Free Subscription Access Interactive Digital Magazine Instant Online Product Information:
new superfast, portable COVID-19 testing method detects the SARS-CoV-2 virus much faster than the currently available methods. Researchers from the University of Florida (Gainesville, FL, USA) and National Chiao Tung University (Hsinchu, Taiwan) have developed a rapid and sensitive testing method for COVID19 biomarkers. The researchers, who previously demonstrated detection of biomarkers relevant in
®
on LinkXpress.com 2 toClick reach reader service portal Mark code(s) of interest on 3 LinkXpress inquiry matrix ®
If your subscription is not renewed every 12 months your Free Subscription may be automatically discontinued
COVID-19 Update . . . . . 4
A
Identify LinkXpress codes of 1 interest as you read magazine
Cont’d on page 14
PerkinElmer to Acquire IDS, Expanding Immunodiagnostics Range erkinElmer, Inc. (Waltham, MA; USA; www.idsplc.com) and Immunodiagnostic Systems Holdings PLC (IDS; Bol-don, Tyne and Wear, UK; www.perkinelmer.com) have reached an agreement whereby PerkinElmer will
P
INSIDE
acquire IDS for approximately USD 155 million. IDS develops, manufactures, and markets innovative immunoassays and automated immunoanalyzer technologies to provide improved diagnostic outcomes for patients. IDS’s imCont’d on page 33
Clinical News . . . . . . . 10 IFCC News . . . . . . . . . 29 Product News . . . . 6-28 Industry News . . . . . . 30 Events Calendar . . . . 34 PUBLISHED IN COOPERATION WITH
International Federation of Clinical Chemistry and Laboratory Medicine
GLOBETECH >>> MEDIA <<<